Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

SHA:688319 Revenue

Chengdu Olymvax Biopharmaceuticals had revenue of 203.52M CNY in the quarter ending June 30, 2026, a decrease of -6.80%. This brings the company's total for the last twelve months to 759.63M, up 13.64% year-over-year. In the year 2025, Chengdu Olymvax Biopharmaceuticals had annual revenue of 704.16M with 19.58% growth. That makes Chengdu Olymvax Biopharmaceuticals the 21,658th largest company in the world by revenue and 3,965th in China.

• Revenue (ttm): 759.63M
• Revenue Growth: +13.64%
• P/S Ratio: 13.98
• Revenue / Employee: 1.74M
• Employees: 436
• Market Cap: 10.90B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	704.16M	115.30M	19.58%
Dec 31, 2024	588.86M	92.74M	18.69%
Dec 31, 2023	496.12M	-51.36M	-9.38%
Dec 31, 2022	547.48M	60.33M	12.38%
Dec 31, 2021	487.15M	167.04M	52.18%

Data Source: S&P Global Market Intelligence Last updated: Aug 17, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 19, 2026

Data Sources Report a data error